Pharmaceuticals, Biotechnology and Life Sciences
Emergex Vaccines and George Mason University’s (Mason) National Center for Biodefense and Infectious Diseases (NCBID) enter into an agreement relating to the development of CD8+ priming RNA virus vaccines.
Agreement targets the development of a cross-reactive vaccine to protect against the most virulent enteroviruses, including enterovirus 71 (EV71)
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has entered into a licensing agreement with Emergex Vaccines Limited, a private UK biotechnology company focused on infectious diseases utilising Midatech’s gold nanoparticle technology.